PerkinElmer

White Paper

Research Spotlight: New Therapeutic Targets Focusing on Aberrant Lipid Metabolism in Alzheimer’s Disease

Therapeutic targets for lipids in alzheimer’s disease

Introduction

As the global population ages and life expectancy increases, neurodegenerative disorders like Alzheimer’s disease (AD) have the potential to overwhelm the healthcare system in the near future. One of the major challenges we currently face is sparse drug discovery pipelines and low clinical trial success rates due to the variability of drug efficacy in individuals. This whitepaper explores new therapeutic targets focusing on Aberrant Lipid Metabolism in Alzheimer's Disease.